Class Action Lawsuit Against Lantheus Holdings
Recently, Johnson Fistel, PLLP has taken significant steps by announcing a class action lawsuit targeting Lantheus Holdings, Inc. (NASDAQ: LNTH). This legal action aims to safeguard the rights of investors who have faced substantial losses due to alleged misleading statements made by the company. Investors who purchased shares of Lantheus between late February 2025 and early August 2025 are directly affected by this situation.
Who is Affected by the Lawsuit?
If you purchased Lantheus securities during the specified class period and experienced financial losses, you are encouraged to act promptly. The deadline for seeking appointment as lead plaintiff in this case is November 10, 2025. Individuals who believe they may qualify, particularly those who sustained considerable financial losses, should evaluate their eligibility for a potential recovery from this lawsuit.
Understanding the Case Against Lantheus Holdings
The crux of the class action revolves around claims that Lantheus Holdings grossly misrepresented key factors about its flagship product, Pylarify. This product serves as a PET imaging agent for prostate cancer and is central to the company’s business strategy. The allegations suggest that the company painted an overly optimistic picture regarding Pylarify’s competitive standing, pricing stability, and future growth prospects.
Impact on Investors Following Disclosure
On May 7, 2025, Lantheus revealed disappointing news regarding Pylarify's sales. The company reported a year-over-year decline, attributing this downturn to a “temporal competitive disruption.” In the wake of this announcement, Lantheus's stock faced a steep drop of over 23%. This was further compounded on August 6, 2025, when the company disclosed that Pylarify's second-quarter sales declined approximately 8.3% year-over-year, necessitating a further reduction in future earnings guidance, which led to an additional stock plunge of nearly 29%. These disclosures and their repercussions are at the heart of the lawsuit, as they significantly impacted the investments of numerous stakeholders.
About Johnson Fistel, PLLP
Johnson Fistel, PLLP stands as a prominent advocate for shareholder rights in the legal landscape. With a robust presence across various states, this law firm has dedicated itself to representing both individual and institutional investors in securities class actions and shareholder derivative lawsuits. In its pursuit of justice, the firm has notably recovered over $90 million for clients in various cases and received recognition as one of the top plaintiff law firms in recent years.
Contact Information for Investors
For further inquiries or assistance related to the lawsuit, investors can reach out to James Baker at (619) 814-4471. Additionally, questions can be directed to Frank J. Johnson at the same number or via email. By facilitating communication, Johnson Fistel aims to ensure that affected investors remain informed and empowered throughout the legal process.
Frequently Asked Questions
What is the goal of the class action lawsuit?
The lawsuit aims to recover losses for investors who purchased Lantheus Holdings securities during the class period and suffered financial damage due to misleading statements made by the company.
When is the deadline to participate in the lawsuit?
Investors must seek appointment as lead plaintiff by November 10, 2025, to be considered for participation in the class action.
What specific claims are being made against Lantheus?
The case alleges that Lantheus Holdings misrepresented the competitive position and growth potential of its product Pylarify.
How did recent disclosures affect Lantheus's stock?
Recent disclosures about declining Pylarify sales resulted in significant stock drops, with a decline over 23% following the May update and nearly 29% after the August report.
Who can I contact for more information about the lawsuit?
For more information, investors can contact James Baker or Frank J. Johnson at Johnson Fistel, PLLP, using the provided phone number.
